← Back to Search

Caffeine Consumption for Glaucoma

N/A

Recruiting

Led By M. Reza Razeghinejad, MD

Research Sponsored by Wills Eye

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 18 to 90 years

Diagnosis of primary open angle glaucoma (Mild, Moderate and Advanced)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, hour 1, hour 2

Awards & highlights

Study Summary

This trial studied the effects of caffeine on blood flow in the eyes of healthy young adults.

Who is the study for?

This trial is for adults aged 18-90 with primary open-angle glaucoma, as well as healthy individuals without eye diseases. It's not suitable for those with conditions affecting eye test results, severe cataracts, nystagmus, macular degeneration (except mild), diabetic retinopathy, certain optic neuropathies or corneal issues, rheumatologic diseases like Raynaud's phenomenon, pregnant or breastfeeding women, mental illness or alcohol addiction.Check my eligibility

What is being tested?

The study is looking at the effects of a caffeine tablet on people with glaucoma compared to healthy subjects. The focus is on how caffeine influences ocular blood flow and potentially affects the vascular system within the eyes.See study design

What are the potential side effects?

Caffeine may cause side effects such as jitteriness, increased heart rate, trouble sleeping (insomnia), upset stomach and restlessness. People who are sensitive to caffeine might also experience headaches and dizziness.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 90 years old.

Select...

I have been diagnosed with primary open angle glaucoma.

Select...

I have healthy eyes with no eye diseases.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, hour 1, hour 2

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, hour 1, hour 2

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, hour 1, hour 2 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Eye

Trial Design

2Treatment groups

Active Control

Group I: Glaucoma PatientsActive Control1 Intervention

Eligible participants include patients with mild, moderate or advanced primary open angle glaucoma (POAG) or primary angle closure glaucoma (PACG). Each participant will complete baseline study tasks. Each participant will then receive one 200 mg caffeine tablet to ingest. Study tasks will be performed 1 hour and 2 hours after caffeine ingestion.

Group II: Healthy controlsActive Control1 Intervention

Eligible participants include healthy subjects with no eye diseases. Each participant will complete baseline study tasks. Each participant will then receive one 200 mg caffeine tablet to ingest. Study tasks will be performed 1 hour and 2 hours after caffeine ingestion.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Wills EyeLead Sponsor

79 Previous Clinical Trials

10,356 Total Patients Enrolled

48 Trials studying Glaucoma

4,916 Patients Enrolled for Glaucoma

M. Reza Razeghinejad, MD5.07 ReviewsPrincipal Investigator - Wills Eye Hospital

Wills Eye

1 Previous Clinical Trials

50 Total Patients Enrolled

1 Trials studying Glaucoma

50 Patients Enrolled for Glaucoma

5Patient Review

This medical professional was very competent and knew exactly what they were doing.

Media Library

Glaucoma Patients Clinical Trial Eligibility Overview. Trial Name: NCT03675412 — N/A

Glaucoma Research Study Groups: Glaucoma Patients, Healthy controls

Glaucoma Clinical Trial 2023: Glaucoma Patients Highlights & Side Effects. Trial Name: NCT03675412 — N/A

Glaucoma Patients 2023 Treatment Timeline for Medical Study. Trial Name: NCT03675412 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent is the patient population involved in this research endeavor?

"Absolutely. According to clinicaltrials.gov, this medical study is in the process of enrolling participants that were initially posted on December 30th 2018. The last update was done on March 3rd 2022 and 80 patients are required from a single location."

Answered by AI

Does this experiment accommodate participants who are of advanced age?

"This study is actively seeking persons aged 18 and above, up to a maximum of 90 years old."

Answered by AI

Do I meet the qualifications to join in this research trial?

"This clinical trial necessitates 80 participants with open-angle glaucoma, aged between 18 and 90. To fulfil their eligibility requirements, patients must fall within that age range."

Answered by AI

Is this clinical experiment currently enlisting participants?

"This clinical trial, which was initially listed on December 30th 2018, is actively recruiting eligible patients. Data hosted on clinicaltrials.gov attests to this and indicates that the study has been recently updated (March 3rd 2022)."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Caffeine Consumption in Glaucoma Patients and Healthy Subjects

M. Reza Razeghinejad MD 2018. "Caffeine Consumption in Glaucoma Patients and Healthy Subjects". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03675412.

All > Glaucoma New York > Glaucoma